Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genzyme Says Work At Allston Plant Will Resume As Planned Later This Month

This article was originally published in The Pink Sheet Daily

Executive Summary

Viral contamination in one of the plant's bioreactors caused a complete shutdown, stopping new production of Cerezyme and Fabrazyme.

You may also be interested in...



Next-Generation Sequencing For Adventitious Virus Detection Helps Speed Response To COVID-19

It's another case where the pandemic spurs adoption of ways to speed the manufacture of vaccines and biologics that have been in development for years.

WHO Proposes Reference Standard For Adventitious Virus Detection

Emerging global standard could speed testing of biologics and gene therapies for stray viral particles, while sparing laboratory animals.

Continued Genzyme Problems Offer Gaucher Opportunity To Competitors

Genzyme's Allston Landing, Mass., plant - currently the only facility that produces its Cerezyme and Fabrazyme drugs - resumed working at full capacity on Aug. 28. But it seems the big biotech's manu-facturing woes are far from over: a mid-August visit by the European Medicines Agency found deficiencies, and a critical FDA inspection is still to come

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS069728

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel